FRAMINGHAM – DPS Group, a privately-owned, global engineering company, and Hodess Cleanroom Construction, a comprehensive cleanroom construction company, today, November 28, announced they have completed a proprietary cell therapy manufacturing facility for Mustang Bio, Inc., a clinical-stage biopharmaceutical company.
Mustang Bio engaged Hodess as prime consultant on the design/build project, and Hodess selected DPS Group for its depth of experience designing current cGMP manufacturing facilities. DPS Group’s office provided architectural and engineering services for the new facility.
Located within UMass Medicine Science Park in Worcester,the 27,000-square-foot facility will support the clinical development and commercialization of Mustang’s CAR T and gene therapy product candidates and enable proprietary cell therapy research. The project focused on upgrading existing office and laboratory space, and converting existing labs into three cGMP ISO7 clinical production areas.
The flexible design met Mustang’s current workplace and manufacturing needs in approximately 12,000-square-feet of the facility, providing ample space for future expansion. Other facility improvements included HVAC, mechanical, and fire protection system upgrades and the installation of a new air handling unit customized for increased air flow to the cGMP spaces. Energy efficient lighting and lighting controls were also added.
“The opening of our cell therapy manufacturing facility is a significant milestone for Mustang Bio because it will enable us to process personalized cell therapies for the treatment of aggressive forms of cancer and continue to advance the research in support of our gene therapy for X-linked severe combined immunodeficiency (X-SCID),” said Manuel Litchman, M.D., president and chief executive officer of Mustang Bio. “DPS Group and Hodess Construction brought a seamless design/build approach and expertise in cleanroom design and construction that helped successfully complete the project. We look forward to growing our clinical and chemistry, manufacturing and controls teams in this specialized facility.”
Serving high-tech industries around the world, DPS designs and builds facilities that turn scientific innovations into life-saving and life-enhancing products. The firm delivers full-service engineering across a range of disciplines, including project management, procurement, design, construction management, health and safety management, commissioning, qualification and facility start-up.
DPS Group is a global engineering, consulting and project management company, serving high-tech industries around the world. It has an office in Framingham.
DPS delivers services for clients across the complete engineering and construction value chain including feasibility studies, concepts, consulting, architecture, engineering, procurement, construction management, commissioning, qualification and validation; as well as contingent staffing solutions.
DPS applies its extensive Process Engineering expertise built over 44 years, as well as significant Lean Construction experience to assist our clients in high-end process sectors such as pharmaceuticals, biotech and semiconductors deliver their manufacturing facilities speedily, safely and cost effectively. What sets us apart are the partnerships we build with our clients through a fundamental understanding of their businesses and our own agility, flexibility, original thinking and our high-caliber people.
Mustang Bio, Inc. (“Mustang”) is a clinical‐stage biopharmaceutical company focused on the development and commercialization of a broad range of proprietary chimeric antigen receptor engineered T cell (CAR T) immunotherapies and gene therapies in areas of unmet need. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, to fund research and development, and to outlicense or bring the technologies to market. Mustang has partnered with top medical institutions to advance the development of CAR T and CRISPR/Cas9-enhanced CAR T therapies across multiple cancers, as well as a lentiviral gene therapy for X-SCID.
Release and photo submitted to SOURCE
Photo credit: Jon Chomitz Photography